These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 20865050)

  • 1. Trastuzumab mediated T-cell response against HER-2/neu overexpressing esophageal adenocarcinoma depends on intact antigen processing machinery.
    Milano F; Guarriera M; Rygiel AM; Krishnadath KK
    PLoS One; 2010 Aug; 5(8):e12424. PubMed ID: 20865050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trastuzumab (Herceptin) enhances class I-restricted antigen presentation recognized by HER-2/neu-specific T cytotoxic lymphocytes.
    Kono K; Sato E; Naganuma H; Takahashi A; Mimura K; Nukui H; Fujii H
    Clin Cancer Res; 2004 Apr; 10(7):2538-44. PubMed ID: 15073134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ERBB2 amplifications in esophageal adenocarcinoma.
    Dahlberg PS; Jacobson BA; Dahal G; Fink JM; Kratzke RA; Maddaus MA; Ferrin LJ
    Ann Thorac Surg; 2004 Nov; 78(5):1790-800. PubMed ID: 15511476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
    Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
    Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. microRNA 125a Regulates MHC-I Expression on Esophageal Adenocarcinoma Cells, Associated With Suppression of Antitumor Immune Response and Poor Outcomes of Patients.
    Mari L; Hoefnagel SJM; Zito D; van de Meent M; van Endert P; Calpe S; Sancho Serra MDC; Heemskerk MHM; van Laarhoven HWM; Hulshof MCCM; Gisbertz SS; Medema JP; van Berge Henegouwen MI; Meijer SL; Bergman JJGHM; Milano F; Krishnadath KK
    Gastroenterology; 2018 Sep; 155(3):784-798. PubMed ID: 29885883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective therapeutic targeting of the overexpressed HER-2 receptor in a highly metastatic orthotopic model of esophageal carcinoma.
    Gros SJ; Kurschat N; Dohrmann T; Reichelt U; Dancau AM; Peldschus K; Adam G; Hoffman RM; Izbicki JR; Kaifi JT
    Mol Cancer Ther; 2010 Jul; 9(7):2037-45. PubMed ID: 20606043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells.
    zum Büschenfelde CM; Hermann C; Schmidt B; Peschel C; Bernhard H
    Cancer Res; 2002 Apr; 62(8):2244-7. PubMed ID: 11956077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of ERBB2 receptor by t-DARPP mediates trastuzumab resistance in human esophageal adenocarcinoma.
    Hong J; Katsha A; Lu P; Shyr Y; Belkhiri A; El-Rifai W
    Cancer Res; 2012 Sep; 72(17):4504-14. PubMed ID: 22745369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
    Menendez JA; Vellon L; Lupu R
    Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathway.
    Herrmann F; Lehr HA; Drexler I; Sutter G; Hengstler J; Wollscheid U; Seliger B
    Cancer Res; 2004 Jan; 64(1):215-20. PubMed ID: 14729627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal antibody to HER-2/neu receptor enhances radiosensitivity of esophageal cancer cell lines expressing HER-2/neu oncoprotein.
    Sato S; Kajiyama Y; Sugano M; Iwanuma Y; Sonoue H; Matsumoto T; Sasai K; Tsurumaru M
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):203-11. PubMed ID: 15629613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma.
    El-Sahwi K; Bellone S; Cocco E; Cargnelutti M; Casagrande F; Bellone M; Abu-Khalaf M; Buza N; Tavassoli FA; Hui P; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Br J Cancer; 2010 Jan; 102(1):134-43. PubMed ID: 19920829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
    Menendez JA; Vellon L; Lupu R
    Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunization with tumor-associated epitopes fused to an endoplasmic reticulum translocation signal sequence affords protection against tumors with down-regulated expression of MHC and peptide transporters.
    Sherritt M; Cooper L; Moss DJ; Kienzle N; Altman J; Khanna R
    Int Immunol; 2001 Mar; 13(3):265-71. PubMed ID: 11222495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma.
    Mimura K; Kono K; Hanawa M; Kanzaki M; Nakao A; Ooi A; Fujii H
    Clin Cancer Res; 2005 Jul; 11(13):4898-904. PubMed ID: 16000588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER-2/neu-derived peptide epitopes are also recognized by cytotoxic CD3(+)CD56(+) (natural killer T) lymphocytes.
    Baxevanis CN; Gritzapis AD; Tsitsilonis OE; Katsoulas HL; Papamichail M
    Int J Cancer; 2002 Apr; 98(6):864-72. PubMed ID: 11948464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endoplasmic reticulum signal sequence facilitated transport of peptide epitopes restores immunogenicity of an antigen processing defective tumour cell line.
    Khanna R; Burrows SR; Argaet V; Moss DJ
    Int Immunol; 1994 Apr; 6(4):639-45. PubMed ID: 7517178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab has anti-metastatic and anti-angiogenic activity in a spontaneous metastasis xenograft model of esophageal adenocarcinoma.
    Lange T; Nentwich MF; Lüth M; Yekebas E; Schumacher U
    Cancer Lett; 2011 Sep; 308(1):54-61. PubMed ID: 21570176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin) in breast cancer cells with Her-2/neu oncogene amplification.
    Menendez JA; Vellon L; Colomer R; Lupu R
    Ann Oncol; 2005 Mar; 16(3):359-71. PubMed ID: 15642702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. rAAV/Her-2/neu loading of dendritic cells for a potent cellular-mediated MHC class I restricted immune response against ovarian cancer.
    Yu Y; Pilgrim P; Zhou W; Gagliano N; Frezza EE; Jenkins M; Weidanz JA; Lustgarten J; Cannon M; Bumm K; Cobos E; Kast WM; Chiriva-Internati M
    Viral Immunol; 2008 Dec; 21(4):435-42. PubMed ID: 19115932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.